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ABSTRACT  Human  ct-thrombin,  the  procoagulant  activation  product  of  prothrombin,  elicits 
chemotaxis in human peripheral blood monocytes and several macrophagelike continuous cell 
lines, most  notably J-774.2,  but  not  in  human  peripheral  blood  granulocytes, a-Thrombin  is 
effective  in stimulating cell movement at concentrations ranging from  10 -t° to 10 -6 M  but is 
optimally active at 10  -8 M. At the latter concentration, the degree of response is equivalent, on 
a molar basis, to that observed with the peptide formylmethionylleucylphenylalanine, (FMP). 
In contrast to thrombin, prothrombin  produces a minimal chemotactic response in monocytes 
and J-774.2.  Blockade of a-thrombin's active center with  diisopropylfluorophosphate  (DIP-F) 
or tryptic  proteolysis of  the  procoagulant exosite  (i.e., 7-thrombin)  fails to  alter chemotactic 
activity.  On  the other  hand,  addition  of  equimolar amounts of  antithrombin  III  (AT3)  to ct- 
thrombin  reduces  thrombin-mediated  chemotaxis  by  60%,  and  increased  ratios  of  AT3  to 
enzyme completely  suppress chemotaxis. We  conclude that thrombin  is a  potent  monocyte 
chemotaxin  and  that  the  domains  in  thrombin  involved  in  stimulating  cell  movement  are 
distinct from  the catalytic site and the fibrin  recognition exosite. These chemotactic domains 
appear to be sequestered in prothrombin  and in the thrombin-AT3 complex and, as such, are 
unavailable to the chemotactic receptor on the monocyte cell membrane. 
Thrombin (EC 3.4.21.5) is a well characterized serine esterase 
generated in the course of initiation of the blood coagulation 
pathways. In addition to its procoagulant activity, expressed 
through the conversion of fibrinogen to fibrin, a-thrombin has 
also been shown to stimulate aggregation and release in blood 
platelets (l, 2) and to elicit a mitogenic response in a variety of 
fibroblast cell lines in tissue culture (3, 4). 
The  migration of leukocytes is a  major component of the 
inflammatory response and is, almost certainly, the result of 
the  directed  movement  of cells  along  a  chemical  gradient 
generated  by  events  at  the  lesion  site  (5).  Recognizing  the 
multiplicity of effects  that  thrombin  has  on  cells,  and  its 
ubiquity at  sites of tissue injury,  we  wondered  whether  the 
enzyme might also be responsible for recruitment of inflam- 
matory cells. In the present communication, we demonstrate 
that a-thrombin is a potent chemotaxin for one of the principal 
inflammatory cells, the monocyte. 
MATERIALS  AND  METHODS 
Human Thrombins:  Human prothrombin complex and highly puri- 
fied human a-thrombin were prepared and characterized as described previously 
(6-8). Specific clotting activity of the ct-thrombin preparation was 3,975 U/mg. 
The  -kthrombin  preparation,  produced  by controlled passage of a-thrombin 
through trypsin immobilized on agarose (7),  was composed of 0.01% n-,  15.7% 
,8-, and 84.3% y-thrombins. It retained 80% of its esterase activity (active site 
titration), but possessed only 1.74 U/mg clotting activity. Diisopropylfluorophos- 
phate-treated thrombin (DIP-thrombin)  was prepared by treating a-thrombin 
repeatedly with 0.2  M  DIP-F at pH 8.0  for 30 min until clotting activity was 
diminished to -0.5  U/mg and active titratable sites were reduced to an unde- 
tectable level (9).  Dilutions of thrombins used in the chemotaxis assays (see 
below) were carried out in Eagle's minimal essential medium with z-glutamine 
(MEM/a-modified), containing 1 mg/ml bovine serum albumin (BSA) and 5 
#M polyethylene glycol 6000 (PEG) (10). 
Human  Peripheral  Blood Monocytes:  Mononuclear  ceils and 
granulocytes were isolated from freshly drawn heparinized blood using a FicoU- 
Hypaque gradient as described by Boyum (11).  The cells were resuspended in 
MEM/a-modified containing 1 mg/ml BSA and 5 ~tM PEG to a final concentra- 
tion of 2.5 x  10  ~ cells/ml. 
Macrophagelike  Cell Lines:  The  cell lines WEHI-3  and J-774.2 
were obtained from American Type Culture Collection (Rockville, MD) and U- 
937 from Dr. Robert Senior (Washington University School of Medicine). Cells 
were grown in RPMl-1640 medium enriched with 10% fetal calf serum FCS. 
Human Antithrombin Ill (AT3):  Human  AT3 was kindly  provided 
by Dr. Craig Jackson, Washington University School of Medicine. It was isolated 
from  normal human  plasma essentially as  previously described  (12).  An  Mr 
-58,000 was assumed (13). 
Thrombin  Characterization:  The  percentage composition of a- 
thrombins was determined by labeling with  ~4C  DIP-F  and  quantitating the 
relative distribution of radioactivity after gel electrophoresis (7). An Mr -36,500 
was assumed for all thrombin forms (6-8).  Active site titrations and clotting 
assays were performed as previously described (6). 
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(Ah|co Mfg. Co., Inc., Southington, CT) by a double micropore membrane 
technique (14). The upper membrane was polycarbonate (Nucleopore Corp., 
Pleasanton, CA), 5-~tm  pore size  (2 #m for granulocytes), and the lower  membrane 
was cellulose  pore size 0.45 ,ttm (Millipore  Corp., Bedford, MA). Chambers were 
prepared and run in triplicate. After an appropriate incubation period at 37°C 
(l h for granulocytes, 2 h for monocytes, and 4 h for cell lines), the membranes 
were removed and stained with liematoxylin.  The extent of cell movement was 
determined by counting the number of ceils per grid at the interface between the 
two membranes using an  eyepiece reticule under 400x magnification. Five 
random grids were scored in each slide preparation. The mean number of ceils 
per high power field (HPF) was corrected by subtracting the counts obtained in 
the absence of any stimulus (negative control). The corrected value, termed net 
cells/HPF, is presented in the text +- SEM. Formylmethionylleucylphenylalanine 
(FMP) (Sigma Chemical Co., St. Louis, MO) at 10  -a M was used as a positive 
control 05). 
RESULTS 
Purified human a-thrombin promotes a dose-dependent migra- 
tion of human  peripheral blood monocytes at  concentrations 
ranging from  10 -~ to  l0 -t° M, with optimal movement occur- 
ring at  l0 -8 M  (Fig.  l,  Table  I).  By contrast,  over the  same 
concentration range, prothrombin elicits minimal migration of 
monocytes (Fig.  1). In most experiments, a-thrombin is equiv- 
alent,  on  a  molar  basis,  to  FMP  in  its  ability  to  stimulate 
monocyte  migration.  However,  whereas  FMP  is chemotactic 
for neutrophils, c~-thrombin is ineffective even at doses as high 
as  l0 -6 M  (data not shown). 
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FIGURE  1  Stimulated migration of human monocytes as a function 
of ~-thrombin  dose.  The  chemotactic activity of prothrombin and 
FMP  are  shown  for comparison.  Each bar  represents  the mean of 
triplicates ±  SEM. 
"Checkerboard analysis" establishes that monocyte response 
to  thrombin  represents  gradient-directed  migration  (chemo- 
taxis) rather than enhanced random cell movement (chemoki- 
nesis).  Only  when  the  thrombin  concentration  in  the  lower 
chamber exceeds that of the upper  (cell-containing) chamber 
does net movement of ceils toward  the lower chamber occur 
(Table I). 
In addition  to  monocytes,  thrombin  stimulates  chemotaxis 
in  several  macrophagelike  cell lines,  including  WEHI-3,  U- 
937, and J-774.2. Data comparing the chemotactic responses of 
this latter cell line with peripheral blood monocytes are shown 
in Table II. It is of interest that the dose of a-thrombin required 
for optimally stimulating cell movement in J-774.2 is the same 
as  it is  for  blood monocytes,  i.e.,  10 -s  M.  Similarly, neither 
blockage of the enzymatic center (DIP-thrombin)  nor modifi- 
cation  of the  procoagulant  exosite  (y-thrombin)  inhibits  the 
ability of thrombin  to stimulate migration of either cell type. 
Thus,  the  ability  of a-thrombin  to  promote  chemotaxis  in 
monocytes or J-774.2 is independent of the enzyme's esterolytic 
and procoagulant capabilities.  Curiously,  DIP-thrombin  con- 
sistently elicits a  35-45%  greater response  in monocytes than 
either  a-thrombin  or 7-thrombin,  when  all are  compared  at 
what  was determined  to be their optimal dose.  On the other 
hand,  both  the optimal  dose  required  for cell migration  and 
the  number  of cells  exhibiting  a  chemotactic  response  are 
approximately  equal  for  all  three  thrombin  preparations  in 
studies with J-774.2. This difference in the behavior of the two 
cell types can  be explained  if it  is assumed  that  (a)  a  larger 
segment of the monocyte population responds to DIP-thrombin 
rather  than  to  a-thrombin  and  that  (b)  this  difference  in 
responsitivity does not exist in the more uniform J-774.2  cell 
line.  Population  heterogeneity has  already  been  documented 
for  monocytes  (16),  but  whether  it  obtains  for  chemotaxis 
remains to be established. 
Because enzymatic inactivation of thrombin does not inhibit 
its  ability  to  act  as  a  chemotaxin,  the  question  arises  as  to 
whether  thrombin  bound  in  a  complex  with  a  physiologic 
inhibitor  would  retain  its  chemotactic  activity.  To  test  this 
possibility,  equimolar amounts  of thrombin  and  purified  hu- 
man  antithrombin  III  (AT3)  were  added  to  the  lower com- 
partments of Boyden chambers in a medium containing 0.5 U/ 
ml heparin as a  catalyst (Organon  Diagnostics, West Orange, 
N J). Cells were placed in the upper compartments with medium 
alone.  As shown  in Fig.  2,  AT3,  in equimolar amounts  with 
c~-thrombin, reduced the chemotactic activity of the enzyme by 
63%. Addition of 10-fold excess AT3 reduced the chemotactic 
activity to  control  levels  (data  not  shown).  By  contrast,  the 
chemotactic activity of DIP-thrombin was unaffected by AT3. 
Moreover, neither AT3 nor heparin alone exhibited significant 
activity as chemotaxins. 
TABLE  I 
Monocyte  Chemotaxis to a- Thrombin  * 
a-Thrombin upper compartment (M) 
a-Thrombin, lower compartment, (M)  ]0  -12 
10-1o 
10  -~ 
10-6 
0  10  12  10-10  10-8  10-6 
~~  --2.4 ±  1.2  3.1  ±  0.4 
-o +14 
90 ±  8.1  130 _  5.2  44_+ 2.3  39 -4- "k8 -----------_1.2 ±  0.5~--- 
* Results are net cell movement/HPF + SEM. n = 12. 
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Comparative  Chemotactic Responses of Monocytes and 
Macrophages  to Thrombins 
Net cell mi- 
Cell type  Chemotaxin  Dose*  gration/H PF:]: 
Monocyte 
J-774.2 
M 
e-thrombin  10  -8  120 +  10 
y-thrombin  10  -7  140 ±  12 
DIP-thrombin  10  -l°  170 ±_ 9 
FMP  10  -6  110 +  8 
e-thrombin  10  -8  93 +  2.8 
y-thrombin  10  -8  99 ±  18 
DIP-thrombin  10  -s  101 +  12 
FMP  10  -8  61 +_ 5 
* Doses  tested  produced  optimal  cell  migration  as  determined  by  dose- 
response curves. 
:1: Representative experiment.  Results  shown  are means of triplicates.  Essen- 
tially identical results have been found in three separate experiments. 
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FIGURE  2  Effect  of addition of equimolar amounts of AT3 on the 
chemotactic activity of a-thrombin  (~)  and DIP-thrombin (DIP) for 
monocytes.  Concentrations  (M)  of  test  substances are  indicated. 
AT3 and heparin (HEP) alone (0.5 U/ml) are shown as controls. Each 
bar represents the mean of triplicates ±  SEM. 
DISCUSSION 
Human peripheral blood monocytes respond chemotactically 
to purified, enzymatically active a-thrombin. This response is 
evident at tbrombin concentrations ranging from 10  -1° to 10  -6 
M  but is most pronounced at  10  -8 M.  On a  molar basis, a- 
thrombin is as potent a  monocyte chemotaxin as FMP at its 
optimal concentration (10 -6 M). 
In contrast to a-thrombin, prothrombin displays little chem- 
otactic activity. This is somewhat surprising because both of 
the  major  cleavage  products  of prothrombin activation, a- 
thrombin and fragment 1.2 (17), are chemotactic for monocytes 
(18). However, these results parallel observations made on the 
chemotactic activity of proteolytic fragments derived from C3 
and C5 that are potent chemotaxins in contrast to the intact 
parent molecules (19). Thus, the tertiary structure of prothrom- 
bin, like that of C3 and C5, must be such that it either precludes 
recognition of its chemotactically active constituents or, assum- 
ing receptor  occupancy, negates the  triggering of secondary 
events essential for cell movement. A similar mechanism may 
be  invoked to explain the  loss  of chemotactic activity of a- 
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thrombin when the latter is complexed with AT3. Because AT3 
is a relatively large molecule (Mr ~58,000) as compared with 
thrombin (Mr ~36,500), we propose that the site or sites  on 
thrombin required for chemotaxis are sequestered coincident 
to complex formation and, as in the case of prothrombin, are 
rendered inaccessible for reaction with putative receptors on 
the monocyte cell membrane. 
The  ability of thrombin to  function as  a  chemotaxin for 
human peripheral blood monocytes stands in sharp contrast 
with other known stimulatory effects  of esterases on cells. For 
these latter events, including  the initiation  of mitotic activity in 
fibroblasts by thrombin (3, 4), and stimulation of cell mobility 
in neutrophils by kallikrein and plasminogen activator (20), 
retention of esterolytic activity is  an  absolute  requirement. 
Finally, the present studies provide evidence for yet another 
important role for thrombin in the biology of wound repair. 
Because  significant  amounts  of  free,  enzymatically  active 
thrombin are known to accumulate within fibrin clots (21), the 
ability of thrombin to  stimulate  monocyte movement may 
provide a mechanism whereby one type of inflammatory cell, 
the monocyte, is recruited to the site of tissue injury. 
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